[go: up one dir, main page]

BR112016007620A2 - composto, medicamento, e, uso de um composto - Google Patents

composto, medicamento, e, uso de um composto

Info

Publication number
BR112016007620A2
BR112016007620A2 BR112016007620A BR112016007620A BR112016007620A2 BR 112016007620 A2 BR112016007620 A2 BR 112016007620A2 BR 112016007620 A BR112016007620 A BR 112016007620A BR 112016007620 A BR112016007620 A BR 112016007620A BR 112016007620 A2 BR112016007620 A2 BR 112016007620A2
Authority
BR
Brazil
Prior art keywords
compound
salt
medicine
medicament
prophylaxis
Prior art date
Application number
BR112016007620A
Other languages
English (en)
Other versions
BR112016007620B1 (pt
Inventor
Kina Asato
hirose Hideki
Kasai Shizuo
Yamasaki Takeshi
Yamashita Tohru
Nishikawa Yoichi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112016007620A2 publication Critical patent/BR112016007620A2/pt
Publication of BR112016007620B1 publication Critical patent/BR112016007620B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

um composto tendo uma ação de antagonista sstr5 e uso do composto como um medicamento são fornecidos. especificamente, um composto representado pela seguinte fórmula: em que cada símbolo é como definido aqui, ou um sal do mesmo, um medicamento que compreende o composto ou um sal do mesmo e o uso do composto ou um sal do mesmo como um agente para a profilaxia ou tratamento de diabetes melito são fornecidos.
BR112016007620-6A 2013-10-07 2014-10-06 Composto, medicamento, e, uso de um composto BR112016007620B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07
JP2013-209826 2013-10-07
PCT/JP2014/005075 WO2015052910A1 (en) 2013-10-07 2014-10-06 Antagonists of somatostatin receptor subtype 5 (sstr5)

Publications (2)

Publication Number Publication Date
BR112016007620A2 true BR112016007620A2 (pt) 2017-08-01
BR112016007620B1 BR112016007620B1 (pt) 2020-05-26

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007620-6A BR112016007620B1 (pt) 2013-10-07 2014-10-06 Composto, medicamento, e, uso de um composto

Country Status (24)

Country Link
US (2) US9353108B2 (pt)
EP (1) EP3055309B1 (pt)
JP (1) JP6411520B2 (pt)
CN (1) CN105612158B (pt)
AR (1) AR097932A1 (pt)
BR (1) BR112016007620B1 (pt)
CA (1) CA2926544C (pt)
CY (1) CY1121163T1 (pt)
DK (1) DK3055309T3 (pt)
ES (1) ES2687102T3 (pt)
HR (1) HRP20181372T1 (pt)
HU (1) HUE039386T2 (pt)
JO (1) JO3442B1 (pt)
LT (1) LT3055309T (pt)
PL (1) PL3055309T3 (pt)
PT (1) PT3055309T (pt)
RS (1) RS57743B1 (pt)
RU (1) RU2671958C2 (pt)
SI (1) SI3055309T1 (pt)
SM (1) SMT201800461T1 (pt)
TR (1) TR201810506T4 (pt)
TW (1) TWI648276B (pt)
UY (1) UY35774A (pt)
WO (1) WO2015052910A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605000B2 (en) * 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
JP6654636B2 (ja) * 2014-12-02 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規ピペリジン誘導体
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
EP4110788A4 (en) 2020-02-28 2024-08-28 Kallyope, Inc. Gpr40 agonists
WO2021230264A1 (ja) * 2020-05-13 2021-11-18 株式会社スコヒアファーマ 胆道系疾患の診断補助・予防・治療剤
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2023125486A1 (zh) * 2021-12-27 2023-07-06 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
WO2024204277A1 (ja) * 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
ATE311386T1 (de) 2001-09-24 2005-12-15 Bayer Pharmaceuticals Corp Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
EP1432710A1 (en) * 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 1, 8-naphthyridine derivatives as antidiabetics
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
CN1902171A (zh) 2003-11-10 2007-01-24 舍林股份公司 用作ccr－5拮抗剂的苄醚胺化合物
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
CA2560111A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006112549A1 (ja) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
WO2007018314A2 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ574038A (en) 2006-06-27 2011-12-22 Takeda Pharmaceutical Fused cyclic compounds as GPR40 receptor function modulators, for treating diabetes
US7754744B2 (en) * 2006-08-15 2010-07-13 Hoffmann-La Roche Inc. Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
AU2007310064B2 (en) 2006-10-19 2013-03-28 Takeda Pharmaceutical Company Limited Indole compound
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
JP2010517935A (ja) 2007-02-09 2010-05-27 武田薬品工業株式会社 Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
US20120041012A1 (en) 2009-05-07 2012-02-16 Aster Susan D Substituted spirocyclic amines useful as antidiabetic compounds
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
SMT201900101T1 (it) 2013-10-29 2019-02-28 Takeda Pharmaceuticals Co Composto eterociclico

Also Published As

Publication number Publication date
RS57743B1 (sr) 2018-12-31
LT3055309T (lt) 2018-08-27
PT3055309T (pt) 2018-10-01
RU2016117732A (ru) 2017-11-15
PL3055309T3 (pl) 2018-10-31
US20160237087A1 (en) 2016-08-18
AR097932A1 (es) 2016-04-20
US9751878B2 (en) 2017-09-05
JO3442B1 (ar) 2019-10-20
TW201536784A (zh) 2015-10-01
CA2926544C (en) 2021-07-06
WO2015052910A1 (en) 2015-04-16
JP2016531950A (ja) 2016-10-13
CA2926544A1 (en) 2015-04-16
US20150099777A1 (en) 2015-04-09
US9353108B2 (en) 2016-05-31
SI3055309T1 (sl) 2018-10-30
TWI648276B (zh) 2019-01-21
ES2687102T3 (es) 2018-10-23
CY1121163T1 (el) 2020-05-29
BR112016007620B1 (pt) 2020-05-26
EP3055309A1 (en) 2016-08-17
SMT201800461T1 (it) 2018-11-09
TR201810506T4 (tr) 2018-08-27
DK3055309T3 (en) 2018-08-27
CN105612158B (zh) 2017-06-30
UY35774A (es) 2015-05-29
EP3055309B1 (en) 2018-06-13
HRP20181372T1 (hr) 2018-10-19
RU2671958C2 (ru) 2018-11-08
HUE039386T2 (hu) 2018-12-28
JP6411520B2 (ja) 2018-10-24
CN105612158A (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
BR112016007620A2 (pt) composto, medicamento, e, uso de um composto
BR112016018548A2 (pt) composto, ácido, medicamento, e, uso de um composto.
BR112018015574A2 (pt) ?composto, medicamento, método para ativar um receptor tipo 2 da orexina e para profilaxia ou tratamento da narcolepsia, e, uso de um composto?
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
BR112016023558A2 (pt) compostos úteis como imunomoduladores
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
BR112017014740A2 (pt) composto espiro tricíclico
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
BR112016018455A2 (pt) composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto.
AR128158A2 (es) Compuesto heterocíclico
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2014, OBSERVADAS AS CONDICOES LEGAIS.